| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Novo Nordisk |
| Information provided by: | Novo Nordisk |
| ClinicalTrials.gov Identifier: | NCT00065130 |
Purpose
The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.
| Condition | Intervention | Phase |
|
Gestational Diabetes |
Drug: Novolog (Insulin Aspart) Drug: Novolin R Drug: Novolin N |
Phase III |
| MedlinePlus related topics: | Diabetes |
| ChemIDplus related topics: | Insulin Insulin aspart Insulin, isophane |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Ages Eligible for Study: At least 18 years old. Subjects older than 35 years old will be considered.
Contacts and Locations More Information
| Study ID Numbers: | ANA-2067 |
| First Received: | July 17, 2003 |
| Last Updated: | December 9, 2005 |
| ClinicalTrials.gov Identifier: | NCT00065130 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
